Biggest Manufacturer，Idasanutlin KK-20（1229705-06-9） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

  2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Idasanutlin KK-20, CAS#1229705-06-9, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 54KG in stock, pls check:

Name:Idasanutlin KK-20

CAS#: 1229705-06-9

Formula: C31H29Cl2F2N3O4 

Exact Mass: 615.15032 

Molecular Weight: 616.48247 

Elemental Analysis: C, 60.40; H, 4.74; Cl, 11.50; F, 6.16; N, 6.82; O, 10.38

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Idasanutlin KK-20Intermediates:

1. Idasanutlin KK-20 Intermediate:3-(3-Chloro-2-fluorophenyl)-2-(4-chloro-2-fluorophenyl)acrylonitrile,

Cas#1219086-87-9

We have more than 65kg in stock, assay 99% in GMP plant, C-GMP standard, 

now COA, NMR, HPLC, MS is ok.

2. Idasanutlin KK-20 Intermediate:Ethyl 4-(2-((3,3-dimethylbutylidene)amino)acetamido)-3-methoxybenzoate

Cas#2034194-92-6

We have more than 68kg in stock, assay 99% in GMP plant, C-GMP standard, 

now COA, NMR, HPLC, MS is ok.

Reference：

1: Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz D, Podlaski F, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B. Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development. J Med Chem. 2013, 56 (14), 5979–5983.

PubMed PMID: 23808545.

Biggest Manufacturer， Ivabradine hydrochloride（148849-67-6） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

 Ivabradine hydrochloride, CAS#148849-67-6, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 36KG in stock, pls check:

Name: Ivabradine hydrochloride

CAS#: 148849-67-6

Formula: C27H37ClN2O5 
Exact Mass: 
Molecular Weight: 505.05 
Elemental Analysis: C, 64.21; H, 7.38; Cl, 7.02; N, 5.55; O, 15.84

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

 Ivabradine hydrochloride Intermediates:

1. Ivabradine hydrochloride Intermediate:3,4-dimethoxy-N-methyl-bicyclo[4.2.0]octa-1,3,5-triene-7-methanamine hydrochloride,
Cas#866783-13-3,
We have more than 46kg in stock, assay 99% in GMP plant, C-GMP standard, 
now COA, NMR, HPLC, MS is ok.

2. Ivabradine hydrochloride Intermediate:3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-Benzazepin-2-one
Cas#85175-59-3,
We have more than 56kg in stock, assay 99% in GMP plant, C-GMP standard,
 now COA, NMR, HPLC, MS is ok.

REFERENCE

1: Dyakov IN, Gleser MG. [Clinical and Economic Efficacy of Ivabradine in Patients Suffered Myocardial Infarction]. Kardiologiia. 2015;55(3):49-55. Russian. PubMed PMID: 26320290.

2: Hancox JC, Melgari D, Dempsey CE, Brack KE, Mitcheson J, Ng GA. hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes. Ther Adv Drug Saf. 2015 Aug;6(4):177-9. doi: 10.1177/2042098615595546. PubMed PMID: 26301071; PubMed Central PMCID: PMC4530352.

3: Lees-Miller JP, Guo J, Wang Y, Perissinotti LL, Noskov SY, Duff HJ. In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating". J Mol Cell Cardiol. 2015 Aug 20;87:192-193. doi: 10.1016/j.yjmcc.2015.08.003. [Epub ahead of print] PubMed PMID: 26299838.

4: Tagliamonte E, Cirillo T, Rigo F, Astarita C, Coppola A, Romano C, Capuano N. Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate. Adv Ther. 2015 Aug 21. [Epub ahead of print] PubMed PMID: 26293212.

5: Melgari D, Brack KE, Zhang Y, El Harchi A, Mitcheson JS, Dempsey CE, Ng GA, Hancox JC. hERG potassium channel inhibition by ivabradine requires channel gating. J Mol Cell Cardiol. 2015 Aug 11;87:126-128. doi: 10.1016/j.yjmcc.2015.08.002. [Epub ahead of print] PubMed PMID: 26275355.

6: Choi HY, Bae KS, Cho SH, Ghim JL, Choe S, Jung JA, Lim HS. Population plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in Korean healthy volunteers. J Clin Pharmacol. 2015 Aug 11. doi: 10.1002/jcph.614. [Epub ahead of print] PubMed PMID: 26265098.

7: Beltrame JF. Ivabradine and the SIGNIFY conundrum. Eur Heart J. 2015 Aug 11. pii: ehv368. [Epub ahead of print] PubMed PMID: 26264551.

8: Reil JC, Bohm M. Can ivabradine still be used in clinical practice after the 'SIGNIFY' trial? Eur Heart J. 2015 Jun 7;36(22):1353-4. PubMed PMID: 26251857.

9: Barzilai M, Jacob G. The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients. Rambam Maimonides Med J. 2015 Jul 30;6(3). doi: 10.5041/RMMJ.10213. PubMed PMID: 26241226; PubMed Central PMCID: PMC4524401.

10: Gómez Casal V, Lage Cendon L, Lago Preciado G, Vara Adrio S. Ivabradine poisoning with suicide intention. Med Intensiva. 2015 Jul 21. pii: S0210-5691(15)00107-2. doi: 10.1016/j.medin.2015.04.008. [Epub ahead of print] English, Spanish. PubMed PMID: 26208765.

11: Chen XP, Zheng HT, Cai WW, Li MK, Zhang JW, Hu J. The Effect of Silibinin on the Pharmacokinetics of Ivabradine and N-Desmethylivabradine in Rats. Pharmacology. 2015;96(3-4):107-11. doi: 10.1159/000435890. Epub 2015 Jul 18. PubMed PMID: 26202095.

12: Glezer MG; LINCOR Program. [Effect of Treatment With Ivabradine on Quality of Life of Patients With Ischemic Heart Disease: Results of the LINCOR Program]. Kardiologiia. 2015;55(2):4-9. Russian. PubMed PMID: 26164981.

13: Liu DQ, Yu JH, Zhang YF, Zhong DF, He L, Chen XY. [Effects of stable isotope labeled internal standard on determination of ivabradine and N-demethylivabradine in human plasma]. Yao Xue Xue Bao. 2015 Mar;50(3):348-54. Chinese. PubMed PMID: 26118116.

14: Kadro W. 2D.09: THE EFFECT OF IVABRADINE ON SILENT AMBULATORY MYOCARDIAL ISCHEMIA. J Hypertens. 2015 Jun;33 Suppl 1:e30. doi: 10.1097/01.hjh.0000467430.64806.58. PubMed PMID: 26102788.

15: Dias da Silva VJ, Tobaldini E, Rocchetti M, Wu MA, Malfatto G, Montano N, Zaza A. Modulation of sympathetic activity and heart rate variability by ivabradine. Cardiovasc Res. 2015 Jun 22. pii: cvv180. [Epub ahead of print] PubMed PMID: 26101263.

16: Cademartiri F, Garot J, Tendera M, Zamorano JL. Intravenous ivabradine for control of heart rate during coronary CT angiography: A randomized, double-blind, placebo-controlled trial. J Cardiovasc Comput Tomogr. 2015 Jul-Aug;9(4):286-94. doi: 10.1016/j.jcct.2015.04.005. Epub 2015 Apr 27. PubMed PMID: 26088378.

17: Kleinbongard P, Gedik N, Witting P, Freedman B, Klöcker N, Heusch G. Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol. 2015 Sep;172(17):4380-90. doi: 10.1111/bph.13220. Epub 2015 Jul 21. PubMed PMID: 26076181.

18: McMurray JJ. It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? Eur Heart J. 2015 Aug 14;36(31):2047-2049. Epub 2015 May 20. Review. PubMed PMID: 25994745.

19: Ivabradine (Corlanor) for heart failure. Med Lett Drugs Ther. 2015 May 25;57(1469):75-6. PubMed PMID: 25989196.

20: Traynor K. Ivabradine approved for stable chronic heart failure. Am J Health Syst Pharm. 2015 Jun 1;72(11):896. doi: 10.2146/news150037. PubMed PMID: 25987676.

Biggest Manufacturer，Lenvatinib mesylate （857890-39-2） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Lenvatinib mesylate , CAS#857890-39-2, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than31KG in stock, pls check:

Name:Lenvatinib mesylate 

CAS#: 857890-39-2

Formula: C22H23ClN4O7S 
Exact Mass: 
Molecular Weight: 522.96 
Elemental Analysis: C, 50.53; H, 4.43; Cl, 6.78; N, 10.71; O, 21.42; S, 6.13

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Lenvatinib mesylate  Intermediates:
1.Lenvatinib mesylate  Intermediate:Methyl 4-chloro-7-methoxyquinoline-6-carboxylate

Cas#205448-66-4,

We have more than 43kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2.Lenvatinib mesylate  Intermediate:4-Chloro-7-methoxyquinoline-6-carboxamide

Cas#417721-36-9 

We have more than 45kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3.Lenvatinib mesylate  Intermediate:1-(2-Chloro-4-hydroxyphenyl)-3-cyclopropylurea

Cas#796848-79-8

We have more than 54kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference：

1: Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 Apr 14. doi: 10.1002/cncr.31344. [Epub ahead of print] PubMed PMID: 29656442.
2: Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S. Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opin Drug Metab Toxicol. 2018 Apr 13:1-7. doi: 10.1080/17425255.2018.1461839. [Epub ahead of print] PubMed PMID: 29617171.
3: De Lisi D, De Giorgi U, Lolli C, Schepisi G, Conteduca V, Menna C, Tonini G, Santini D, Farolfi A. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? Expert Opin Drug Metab Toxicol. 2018 Mar 23:1-7. doi: 10.1080/17425255.2018.1455826. [Epub ahead of print] PubMed PMID: 29557694.
4: Groden PJ, Lee TC, Bhattacharyya S, Connors J, Lorch J. Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma. Front Med (Lausanne). 2018 Feb 23;4:220. doi: 10.3389/fmed.2017.00220. eCollection 2017. PubMed PMID: 29527527; PubMed Central PMCID: PMC5829091.
5: Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018 May;39(5):2225-2234. doi: 10.3892/or.2018.6306. Epub 2018 Mar 8. PubMed PMID: 29517103.
6: Kimura-Tsuchiya R, Sasaki E, Nakamura I, Suzuki S, Kawana S, Okouchi C, Fukushima T, Hashimoto Y, Suzuki S, Saji S. A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib. Case Rep Oncol. 2018 Feb 9;11(1):75-80. doi: 10.1159/000486569. eCollection 2018 Jan-Apr. PubMed PMID: 29515414; PubMed Central PMCID: PMC5836208.
7: Nervo A, Gallo M, Samà MT, Felicetti F, Alfano M, Migliore E, Marchisio F, Berardelli R, Arvat E, Piovesan A. Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice. Anticancer Res. 2018 Mar;38(3):1643-1649. PubMed PMID: 29491097.
8: Thomas H. Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):190. doi: 10.1038/nrgastro.2018.20. Epub 2018 Feb 28. PubMed PMID: 29487423.
9: Ferrari SM, Ruffilli I, Centanni M, Virili C, Materazzi G, Alexopoulou M, Miccoli M, Antonelli A, Fallahi P. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. Recent Pat Anticancer Drug Discov. 2018 Feb 19. doi: 10.2174/1574892813666180220110729. [Epub ahead of print] PubMed PMID: 29468981.
10: Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PubMed PMID: 29433850.
11: Reig M, Bruix J. Lenvatinib: can a non-inferiority trial change clinical practice? Lancet. 2018 Mar 24;391(10126):1123-1124. doi: 10.1016/S0140-6736(18)30208-3. Epub 2018 Feb 9. PubMed PMID: 29433849.
12: Nishi T, Igawa A, Nishimura A, Hakamada K. [A Case of a Rupture of the Carotid Artery Caused by the Lenvatinib Medication]. Gan To Kagaku Ryoho. 2017 Nov;44(12):1610-1612. Japanese. PubMed PMID: 29394718.
13: Suyama K, Tomiguchi M, Takeshita T, Sueta A, Yamamoto-Ibusuki M, Shimokawa M, Yamamoto Y, Iwase H. Factors involved in early lenvatinib dose reduction: a retrospective analysis. Med Oncol. 2018 Jan 31;35(3):19. doi: 10.1007/s12032-018-1088-5. PubMed PMID: 29387983.
14: Lenvatinib. Aust Prescr. 2017 Dec;40(6):242-243. doi: 10.18773/austprescr.2017.070. Epub 2017 Oct 3. Review. PubMed PMID: 29375189; PubMed Central PMCID: PMC5768601.
15: Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, Güthner C, Zimmermann S, Weidner S, Pless M, Stenner F, Rothschild SI. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. J Cancer. 2018 Jan 1;9(2):250-255. doi: 10.7150/jca.22318. eCollection 2018. PubMed PMID: 29344270; PubMed Central PMCID: PMC5771331.
16: Lee YS, Kim SM, Kim BW, Chang HJ, Kim SY, Park CS, Park KC, Chang HS. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. Neoplasia. 2018 Feb;20(2):197-206. doi: 10.1016/j.neo.2017.12.003. Epub 2018 Jan 12. PubMed PMID: 29331886; PubMed Central PMCID: PMC5767911.
17: Wei X, Zhang T, Yao Y, Zeng S, Li M, Xiang H, Zhao C, Cao G, Li M, Wan R, Yang P, Yang J. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD. Exp Eye Res. 2018 Mar;168:2-11. doi: 10.1016/j.exer.2017.12.009. Epub 2017 Dec 25. PubMed PMID: 29284110.
18: Kudo M. Lenvatinib in Advanced Hepatocellular Carcinoma. Liver Cancer. 2017 Nov;6(4):253-263. doi: 10.1159/000479573. Epub 2017 Aug 29. PubMed PMID: 29234629; PubMed Central PMCID: PMC5704706.
19: Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma. Intern Med. 2018 Apr 1;57(7):1015-1019. doi: 10.2169/internalmedicine.9593-17. Epub 2017 Dec 8. PubMed PMID: 29225265.

20: Morelli S, Puxeddu E. Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient. Drugs Context. 2017 Jul 26;6:212310. doi: 10.7573/dic.212310. eCollection 2017. PubMed PMID: 29167691; PubMed Central PMCID: PMC5699105.

Biggest Manufacturer， Pimavanserin tartrate（706779-91-1） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

 Pimavanserin tartrate, CAS#706779-91-1, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than56KG in stock, pls check:

Name: Pimavanserin tartrate

CAS#: 706779-91-1

Formula: C25H34FN3O2 
Exact Mass: 427.26351 
Molecular Weight: 427.56 
Elemental Analysis: C, 70.23; H, 8.02; F, 4.44; N, 9.83; O, 7.48

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

 Pimavanserin tartrate Intermediates:

1.  Pimavanserin tartrate Intermediate:4-(4-fluorobenzylamino)-1-methylpiperidine 

Cas#359878-47-0 

We have more than67kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2.  Pimavanserin tartrate Intermediate:p-Isobutyloxybenzylamin acetate

Cas#955997-89-4

We have more than 58kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference：

1: Chendo I, Ferreira JJ. Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opin Pharmacother. 2016 Oct;17(15):2115-24. doi: 10.1080/14656566.2016.1234609. Epub 2016 Sep 15. PubMed PMID: 27609312.

2: Hussar DA, Dimaculangan CA. Reslizumab, ixekizumab, and pimavanserin tartrate. J Am Pharm Assoc (2003). 2016 Sep-Oct;56(5):595-8. doi: 10.1016/j.japh.2016.08.002. PubMed PMID: 27594111.

3: Stahl SM. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016 Aug;21(4):271-5. doi: 10.1017/S1092852916000407. PubMed PMID: 27503570.

4: Markham A. Pimavanserin: First Global Approval. Drugs. 2016 Jul;76(10):1053-7. doi: 10.1007/s40265-016-0597-9. PubMed PMID: 27262680.

5: Traynor K. Pimavanserin approved for Parkinson's-related hallucinations, delusions. Am J Health Syst Pharm. 2016 Jun 15;73(12):853. doi: 10.2146/news160037. PubMed PMID: 27261226.

6: Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther. 2016 Jun 6;58(1496):74-5. PubMed PMID: 27249096.

7: Howland RH. Pimavanserin: An Inverse Agonist Antipsychotic Drug. J Psychosoc Nurs Ment Health Serv. 2016 Jun 1;54(6):21-4. doi: 10.3928/02793695-20160523-01. PubMed PMID: 27245248.

8: Banks ML. Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys. Drug Alcohol Depend. 2016 Aug 1;165:260-4. doi: 10.1016/j.drugalcdep.2016.05.014. Epub 2016 May 27. PubMed PMID: 27242287; PubMed Central PMCID: PMC4939103.

9: Hermanowicz S, Hermanowicz N. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Expert Rev Neurother. 2016 Jun;16(6):625-33. doi: 10.1586/14737175.2016.1158102. PubMed PMID: 26908168.

10: Hunter NS, Anderson KC, Cox A. Pimavanserin. Drugs Today (Barc). 2015 Nov;51(11):645-52. doi: 10.1358/dot.2015.51.11.2404001. Review. PubMed PMID: 26744739.

11: Andersen VL, Hansen HD, Herth MM, Dyssegaard A, Knudsen GM, Kristensen JL. (11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. Bioorg Med Chem Lett. 2015 Mar 1;25(5):1053-6. doi: 10.1016/j.bmcl.2015.01.017. Epub 2015 Jan 20. PubMed PMID: 25655720.

12: Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochem Res. 2014 Oct;39(10):2008-17. doi: 10.1007/s11064-014-1293-3. Epub 2014 Mar 30. Review. PubMed PMID: 24682754; PubMed Central PMCID: PMC4172996.

13: Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest. 2013 Dec;123(12):4986-91. doi: 10.1172/JCI70678. Epub 2013 Dec 2. Review. PubMed PMID: 24292660; PubMed Central PMCID: PMC3859385.

14: Kingwell K. Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease. Nat Rev Neurol. 2013 Dec;9(12):658. doi: 10.1038/nrneurol.2013.233. Epub 2013 Nov 19. PubMed PMID: 24247322.

15: Fox SH. Pimavanserin as treatment for Parkinson's disease psychosis. Lancet. 2014 Feb 8;383(9916):494-6. doi: 10.1016/S0140-6736(13)62157-1. Epub 2013 Nov 1. PubMed PMID: 24183566.

16: Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1. Erratum in: Lancet. 2014 Jul 5;384(9937):28. PubMed PMID: 24183563.

17: Friedman JH. Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opin Pharmacother. 2013 Oct;14(14):1969-75. doi: 10.1517/14656566.2013.819345. Review. PubMed PMID: 24016069.

18: Hubbard D, Hacksell U, McFarland K. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios. Behav Pharmacol. 2013 Oct;24(7):628-32. doi: 10.1097/FBP.0b013e3283656db6. PubMed PMID: 23969614.

19: Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012 Nov;141(2-3):144-52. doi: 10.1016/j.schres.2012.07.029. Epub 2012 Sep 4. PubMed PMID: 22954754.

20: Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Behav Pharmacol. 2012 Aug;23(4):426-33. doi: 10.1097/FBP.0b013e3283566082. PubMed PMID: 22750845.

Biggest Manufacturer，Acalabrutinib（1420477-60-6） and Intermediates.

EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.

EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.

2018 Korea CPHI, C30

EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com  TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.

1.

Acalabrutinib, CAS#1420477-60-6, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 13KG in stock, pls check:

Name:Acalabrutinib

CAS#: 1420477-60-6

Formula: C26H23N7O2 
Exact Mass: 465.19132 
Molecular Weight: 465.52 
Elemental Analysis: C, 67.08; H, 4.98; N, 21.06; O, 6.87

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

2. 

Acalabrutinib Intermediates:

1. Acalabrutinib Intermediate:(3-chloropyrazin-2-yl)methanamine dihydrochloride

Cas#867165-53-5

We have more than 23kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

2. Acalabrutinib Intermediate:(S)-benzyl-2-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate

Cas#1420478-87-0

We have more than 33kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

3. Acalabrutinib Intermediate:(S)-benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine
-1-carboxylate

Cas#1420478-88-1

We have more than 16kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

4. Acalabrutinib Intermediate:4-(pyridin-2-yl-aminocarbonyl)benzeneboronic acid

Cas#850568-25-1

We have more than 5kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

5. Acalabrutinib Intermediate:N-Pyridin-2-yl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide

Cas#1383385-64-5

We have more than 23 kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.

Reference：

1: Maly J, Blachly JS. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. Curr Hematol Malig Rep. 2016 Feb 11. [Epub ahead of print] PubMed PMID: 26893063.

2: Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7. PubMed PMID: 26641137.